CBA-1535 / Chiome Biosci - LARVOL DELTA

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Chiome Bioscience Inc.

Biomarker • New P1 trial • Oncology • Solid Tumor

Preclinical characterization of CBA-1535, a novel bi-specific tribody, with two binding sites to 5T4 and one site to CD3ε (AACR 2023) - "These results provide the strong rationale for further clinical evaluation ofCBA-1535 in 5T4 positive tumors. CBA-1535 is now under the phase 1 trial in Japan (jRCT2031210708), with 2 parts, the monotherapy and the combination with Pembrolizumab."

IO biomarker • Preclinical • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • AIF1 • CD69 • IL2 • IL2RA • IL6 • TNFA • TPBG

Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. (PubMed, J Exp Clin Cancer Res) - "The novel tribodies have the potential to become strong and safe therapeutic drugs, allowing to reduce also the cost of production as one single molecule contains three different specificities including the anti-TAA, anti-CD3 and anti-IC binding arms."

Journal • Preclinical • Immune Modulation • Inflammation • Oncology • LAG3